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Abstract: 
 
Background: Pasteurized donor human milk (PDHM) is the recommended feeding alternative 
for preterm infants when mother's own milk is not available. Use of PDHM in United States 
neonatal hospitals is increasing, although guidelines for the refrigerated and frozen storage are 
limited. Objective: We aimed to review the current evidence for the storage of Holder PDHM 
(HPDHM) under refrigerated and frozen storage conditions. Methods: A systematic review of 
the literature was conducted for studies published between 1985 and May 2018. Studies were 
included if they studied the storage of Holder-pasteurized human milk under refrigerated or 
frozen storage conditions. Results: Fourteen studies met the inclusion criteria. Five studies 
addressed refrigerated storage and nine studies addressed frozen storage. There was little overlap 
in the outcomes measured or the analytical methods employed. There was concordance in three 
studies reporting no microbial growth over 4–9 days of refrigerated storage, and in five studies 
reporting a reduction in fat during 1–8 months of frozen storage. Only one study assessed the 
storage of HPDHM that had been fortified. Conclusions: Long-term refrigerated and frozen 
storage of HPDHM affects some components in milk more than others. While there is evidence 
of microbial purity during four or more days of refrigerated storage in clinical conditions, there is 
limited research on the impact of macro and micronutrients, or the impact of fortifiers. More 
research is needed in these areas. 
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Article: 
 
Introduction 
 
According to a 2017 policy statement published by the American Academy of Pediatrics, the use 
of pasteurized donor human milk (PDHM) distributed by milk banks is recommended for infants 
weighing <1,500 g when a mother's own milk is unavailable or insufficient.1 The use of PDHM 
is associated with reduced healthcare costs,2 better health outcomes,3–5 and a reduced risk of the 
development of necrotizing enterocolitis.6 Results from the Center for Disease Control's 2015 
Maternity Practices in Infant Nutrition and Care survey indicated that, two-thirds of neonatal 
intensive care hospitals were using donor human milk, and over 90% were using fortifiers to 
increase the nutrient content of human milk (HM).7 
 
The pasteurization of donor HM is common practice among milk banking organizations, 
primarily to remove infectious contaminants and reduce the growth of harmful bacteria.8,9 This is 
an appropriate concern given that PDHM is often fed to preterm infants who have compromised 
immune systems.10 The Holder method of pasteurization is the predominating procedure used by 
milk banks internationally and involves heating the HM to 62.5–63°C for 30 minutes.11–14 Holder 
pasteurization of HM has been well studied. While the process does indeed partially diminish 
several important biological components, such as immunoglobulins and the activity of lipase 
enzymes, macronutrients are almost fully retained.9 
 
Less is known about what happens to Holder PDHM (HPDHM) over the course of long-term 
storage. While the Academy of Breastfeeding Medicine has issued storage recommendations for 
raw HM fed to healthy infants in home settings,15 recommendations regarding the storage of 
HPDHM for use in a clinical setting with medically fragile infants are scarce. Understanding 
appropriate storage conditions for HPDHM in a clinical setting is an important area of research. 
 
In 2011, the Human Milk Banking Association of North America (HMBANA) issued guidelines 
recommending that thawed HPDHM should be stored at 4°C and used within 24 hours.11 Based 
on international guidelines outlining milk banking protocols, the maximum recommended frozen 
storage (−20°C) time for HPDHM is 3–6 months.12,13,16,17 According to the 2018 HMBANA 
guidelines, frozen HPDHM expires 1 year after the earliest pumping date of milk within the 
pool.18 HPDHM is a valuable commodity with a short shelf-life. Affordability was the most 
frequently cited barrier of nonuse in a 2013 survey of 183 Level 3 neonatal intensive care units 
(NICUs).19 Research to evaluate the feasibility of extending HPDHM expiration dates has the 
potential to reduce cost barriers associated with a short shelf-life and product waste. 
 
The purpose of this article is to review the current evidence for the storage of HPDHM under 
refrigerated and frozen storage conditions. 
 
Methods 
 
Search process 
 
This review of published literature was conducted through electronic searches of PubMed, 
Scopus, Science Direct, Google Scholar, ProQuest Central, and WorldCat Discovery. The 
electronic search included the following keywords and MeSH terms: (i) human milk; (ii) breast 
milk; (iii) donor milk; (iv) PDHM; (v) milk banks AND storage; (vi) (donor milk OR human 
milk) AND pasteurization; (vii) (donor milk OR human milk) AND storage; (viii) (donor milk 
OR human milk) AND refrigerated storage; (ix) (donor milk OR human milk) AND frozen 
storage; (x) (donor milk OR human milk) AND (storage OR pasteurization); (xi) (donor milk OR 
human milk) AND (storage OR bank) AND pasteurization; (xii) (human milk OR human milk) 
AND (storage OR pasteurization) AND (bioactive OR immune OR antimicrobial); and (xiii) 
(donor milk OR human milk) AND (storage OR freez* OR refrig* OR processing) AND 
(pasteuriz*). 
 
Inclusion and exclusion criteria 
 
To be included in this review, a study must have been published between 1985 and May 2018, 
when the search was conducted. This cutoff date was chosen based on the establishment of 
HMBANA and its milk processing protocols. Studies were required to be peer reviewed and 
include the primary outcome of the effects of extended storage, either under frozen (typically 
−20°C) or refrigerated (typically 4°C) conditions. Only studies examining donor HM that had 
undergone the Holder method of pasteurization were included, whether explicitly stated or as 
evidenced by the processing protocol used at the milk bank from which it was acquired. HPDHM 
fortified with HM fortifiers were also included. Studies assessing colostrum were not included. 
Studies were also excluded if they did not describe the length of storage time at a given 
temperature or the method of pasteurization employed, if they did not report outcomes 
specifically for HPDHM, or if the heat sterilization process differed from the Holder method, 
such as high temperature–short time, ultra-high temperature, or extended shelf life. 
 
Data extraction 
 
The following information was extracted for each study: author; year; title; type of milk; sample 
size; fortification status; storage temperature; storage duration; outcomes measured; and 
findings. Two researchers independently reviewed all studies for inclusion/exclusion criteria and 
results, and differences were resolved through discussion. 
 
Results 
 
Initially, 19 studies that included HPDHM were identified. Three (16%) did not describe the 
length of storage time,20–22 one (5%) did not report outcomes specifically for HPDHM,23 and one 
(5%) was not peer reviewed,24 leaving a final total of 14 studies included in this review (Table 
1). 
 
Refrigerated storage of HPDHM 
 
Five studies examined the storage of unfortified HPDHM under refrigerated conditions (Table 
2). Storage times ranged from 24 hours to 90 days, and analytes assessed included microbial 
growth, total protein, bactericidal capacity, lysozyme activity, secretory immunoglobulin A 
(sIgA) activity, and total ganglioside concentrations. One of these studies included pilot 
information on fortified HPDHM, although significance was not independently assessed.28 
 
  
Table 1. Summary of Refrigerated and Frozen Storage Studies Using Holder-Pasteurized Donor 
Human Milk 
Author(s) Year 
Storage 
conditions 
(°C) 
Storage 
duration Sample size Outcome(s) measured 
Lepri et al.25 1997 −20 90 Days n = 16 single-
donor samples 
Lipids: modified Folch method, and thin-layer and 
gas chromatography 
l-lactate: biosensor 
Degree of lipolysis: gas chromatography 
Silvestre et 
al.26 
2008 4–6 72 Hours n = 10 single-
donor samples 
Bactericidal capacity: Escherichia coli viability 
assay 
Vieira et al.27 2011 −20 24 Hours n = 57 single-
donor samples 
Macronutrients: Infrared human milk analyzer 
(MilkOScan by Foss) 
Cohen et 
al.28 
2012 4 122 Hours n = 22 previously 
pooled samples 
Bacterial growth: standard plate count method 
García-Lara 
et al.29 
2013 −20 180 Days n = 34 individual 
samples from 28 
donors 
Macronutrients: Infrared Human Milk Analyzer 
(MIRIS, Sweden) 
Vázquez-
Román et 
al.30 
2014 −20 90 Days n = 36 Fat and energy content: creamatocrit (Lucas method) 
Borgo et al.31 2015 −18 240 Days n = 1 sample from 
single donor 
Saturated and unsaturated FA: gas chromatography, 
nuclear magnetic resonance, infrared spectroscopy 
Vickers et 
al.32 
2015 4 0–96 
Hours, 9 
Days 
n = 42 previously 
pooled samples 
(2–5 donors per 
pool) 
Bacterial growth: HMBANA Standard Operating 
Procedure for Culturing PDHM 
Marinković 
et al.33 
2016 −20 30 Days n = 10 single-
donor samples 
Antioxidative properties: static oxidation–reduction 
potential (ORP) measurement; oxygen radical 
absorbance capacity (ORAC) assay; Reflectoquant 
ascorbic acid test; electron paramagnetic resonance 
spin-trapping spectroscopy 
Vázquez-
Román et 
al.34 
2016 −20 3 Months n = 40 previously 
pooled samples 
Dornic acidity: titration 
Meng et al.35 2016 4 7 Days n = 13 single-
donor samples 
Aerobic bacteria and coliform count: Petrifilm 
Total protein: Bicinchoninic acid (BCA) assay 
Lysozyme activity: Micrococcus 
lysodeikticus based turbidimetric assay 
IgA activity: kinetic ELISA 
Kanaprach et 
al.36 
2018 −20 6 Months n = 40 single-
donor samples 
Intestinal cell growth-promoting activity: fetal 
intestinal growth assay 
Antimicrobial effect against E. coli: antimicrobial 
assay 
Salcedo et 
al.37 
2018 4 90 Days n = 5 single-donor 
samples 
Gangliosides concentrations: ultrahigh-performance 
liquid chromatography–tandem mass spectrometry 
(UHPLC-MS/MS) 
de Waard et 
al.38 
2018 −20 12 Months n = 34 single-
donor pools 
Bacterial growth: blood and CLED agar 
Macronutrients: Human Milk Analyzer (MIRIS, 
Sweden) 
HMBANA, Human Milk Banking Association of North America; ELISA, enzyme-linked immunosorbent assay; 
IgA, immunoglobulin A; PDHM, pasteurized donor human milk; FA, fatty acid; CLED, cysteine- lactose- and 
electrolyte-deficient. 
 
Table 2. Effects of Extended Refrigerated Storage on Components of Holder-Pasteurized Donor 
Human Milk 
Component Duration Findings Author 
Microbial growth 24–122 Hours No significant change Cohen et al.28, a 
7 Days No significant change Meng et al.35 
9 Days No significant change Vickers et al.32 
Total protein 7 Days No significant change Meng et al.35 
Bactericidal capacity 72 Hours No significant change Silvestre et al.26 
Lysozyme activity 7 Days No significant change Meng et al.35 
IgA activity 7 Days No significant change Meng et al.35 
Gangliosides       
 GM3 90 Days No significant change Salcedo et al.37 
 GD3 90 Days No significant change Salcedo et al.37 
 Total gangliosides 90 Days No significant change Salcedo et al.37 
aIndicates studies that also included fortified Holder-pasteurized donor human milk. 
 
Effects on microbial growth. Currently, there is no consensus definition of “acceptable levels” 
of bacteria in HM and special considerations must be made for infants in the NICU with 
compromised immune systems. Regarding healthy, term infants, Meng et al.35 suggest two 
options: (i) use the levels set for Pasteurized Milk Ordinance (PMO) for Grade A pasteurized 
bovine milk (4.30 log colony-forming unit [CFU]/mL), or (ii) set the maximum level as that 
which is present in the milk in a feeding container immediately after exposure to the microflora 
in an infant's mouth through bottle or cup feeding (average 2.8 log CFU/mL). In their 2016 
study, Meng et al.35 found that, after 7 days of storage at 4°C, HPDHM consistently had bacterial 
levels below both the PMO standard and the more stringent constraints set in option 2. The 
aerobic bacteria count for HPDHM stored at 4°C was 0.0 log CFU/mL at all time points up to 7 
days.35 
 
These data support similar findings by Cohen et al. who, in a 2012 study, found no bacterial 
growth in 22 samples of HPDHM that were thawed and refrigerated for 24–122 hours of routine 
NICU handling.28 However, 33% (2/6) bottles of fortified HPDHM exhibited bacterial growth. A 
2015 study by Vickers et al.32 found that there was no evidence of microbial growth in HPDHM 
when thawed and stored at 4°C for up to 9 days. This study utilized 42 randomly selected 
samples of HPDHM from a HMBANA milk bank. Study milk handling protocol aimed to mimic 
that which may be found in an NICU feeding room and, on average, the refrigerator was opened 
27 times per day.32 These data suggest that unfortified HPDHM maintains its antimicrobial 
defenses and remains free of microbial growth when stored at 4°C for up to 9 days. 
 
Effects on macronutrient concentration. One published study has addressed the retention of 
macronutrients during refrigerated storage of HPDHM, and only protein concentration was 
assessed. In the 2016 study by Meng et al., HPDHM stored at 4°C exhibited no significant 
change in total protein concentration (p = 0.27) between 0 and 7 days.35 
 
Effects on bactericidal capacity and bioactive factors. There are two studies that examine the 
impact of refrigerated storage on bactericidal capacity and the activity of immunological factors 
in HPDHM. In their 2008 study, Silvestre et al. determined that the bactericidal capacity of 
HPDHM against Escherichia coli exhibited no significant changes during 72 hours of 
refrigerated storage (at 4–6°C).26 In 2016, Meng et al. reported no significant changes in the 
activity of lysozyme (p = 0.77) and sIgA (p = 0.49) after 7 days of refrigerated storage.35 
In 2018, Salcedo et al.37 published a study looking at the effects of heat treatment and storage 
time on the concentration of gangliosides in HM. Gangliosides are glycolipids primarily 
associated with the milk fat globule membrane, and their content and profile constituents vary 
throughout lactation. GD3 (Neu5Ac α2-8 Neu5Ac α2-3 Gal β1-4Glc β1-1 ceramide) is most 
abundant during the first few days of lactation, whereas GM3 (Neu5Ac α2-3 Gal β1-4Glc β1-1 
ceramide) is found in the highest proportion in mature HM.39 Salcedo et al. found that storage for 
up to 90 days at 4°C had no significant impact on either total or specific ganglioside content in 
HPDHM.37 
 
Table 3. Effects of Extended Frozen Storage at −20°C on Components of Holder-Pasteurized 
Donor Human Milk 
Component Duration Findings Author 
Bacterial growth 8 Months No significant growth de Waard et al.38 
Total protein 24 Hours Significant decrease Vieira et al.27 
8 Months Significant increase de Waard et al.38 
Nitrogen 6 Months No significant change García-Lara et al.29 
Total carbohydrate 6 Months Significant decrease García-Lara et al.29 
8 Months No significant change de Waard et al.38 
Lactose 24 Hours No significant change Vieira et al.27 
l-Lactate 90 Days Decrease (significance not assessed) Lepri et al.25 
Total fat 24 Hours Significant decrease Vieira et al.27 
3 Months Significant decrease Lepri et al.,25 Vázquez-Román et al.30 
6 Months Significant decrease García-Lara et al.29 
8 Months No significant change de Waard et al.38 
Fatty acids 240 Days Varied by fatty acid Borgo et al.31 
Degree of lipolysis 3 Months Increase (significance not assessed) Lepri et al.25 
Energy 3 Months Significant decrease Vázquez-Román et al.30 
6 Months Significant decrease García-Lara et al.29 
8 Months No significant change de Waard et al.38 
Bactericidal capacity 3 Months No significant change Kanaprach et al.36 
6 Months Significant decrease Kanaprach et al.36 
Antioxidative properties 
 Superoxide dismutase 30 Days No significant change Marinković et al.33 
 Glutathione peroxidase 30 Days No significant change Marinković et al.33 
 Glutathione reductase 30 Days No significant change Marinković et al.33 
 Ascorbate concentration 30 Days No significant change Marinković et al.33 
Dornic acidity 3 Months Non-clinically significant decrease Vázquez-Román et al.34 
Intestinal cell growth-promoting activity 6 Months No significant change Kanaprach et al.36 
 
Frozen storage of HPDHM 
 
While storing raw and pasteurized HM at −80°C minimizes changes to many properties, it is 
impractical for milk banks and neonatal units primarily due to its expense.40,41 Freezer storage at 
−20°C is much more commonplace. This section summarizes the findings from the nine studies 
published examining the impact of frozen storage conditions on pH and microbial growth, as 
well as the retention of macronutrients, immunological activity, and enzymatic activity (Table 3). 
 
Effects on microbial growth. Only one study assessed microbial growth in HPDHM under 
frozen storage conditions. In a 2018 study, de Waard et al. found that HPDHM stored at −20°C 
for 12 months remained free of microbial growth for the first 8 months.38 Microbial analysis at 
10 and 12 months revealed positive cultures in HPDHM samples from 17% to 28% of donors; 
however, study samples were drawn postpasteurization and it was unclear whether this occurred 
under sterile conditions, which may have influenced results. 
 
Effects on macronutrient concentrations. Six published studies have assessed the impact of 
frozen storage on macronutrient retention in HPDHM. Five studies examined total fats, three 
examined total protein or nitrogen, three assessed carbohydrates, and one assessed individual 
fatty acid profiles. 
 
A 1997 study by Lepri et al.25 found that, between 0 and 35 days of frozen storage, total fat 
content of HPDHM decreased only slightly (25.08 mg/mL ±0.54 to 24.67 mg/mL ±0.52), then 
notably after 70 (23.60 mg/mL ±0.58) and 90 days (23.32 mg/mL ±0.55) of frozen storage. This 
represented a −7.55% change between baseline and day 90.25 
 
Others have also reported a decline in the fat content of HPDHM during extended frozen storage. 
In a 2011 study by Vieira et al., after 24 hours of storage at −20°C, HPDHM showed significant 
decreases in mean fat (5.5%, p < 0.001) compared with never-frozen HPDHM.27 In their 2013 
study, García-Lara et al. found that there were small but significant decreases in the fat 
(−0.13 g/dL, 2.8% relative decrease, p = 0.001) and energy (−1.55 kcal/dL, or −0.46 kcal/oz, 
2.2% relative decrease, p = 0.001) content of HPDHM after 180 days of frozen 
storage.29 Importantly, authors noted that, while these declines were of low magnitude, when the 
impact of pasteurization on fat content was taken into account (3.5% relative decrease), the total 
reduction was 6.2%. This reveals a more clinically relevant issue with regard to the retention of 
energy for preterm infants who are the primary recipients of HPDHM, given a potentially 
cumulative detrimental impact associated with multiple processes, including pasteurization and 
storage. 
 
In their 2014 study, Vázquez-Román et al. found that the fat content of HPDHM decreased by 
0.39 g/dL (−15.08% relative change, p = 0.01) after 30 days of frozen storage, but there was no 
significant change at 60 days (0% relative decrease, p = 0.996) or 90 days (+6.5% relative 
change; p = 0.580) of frozen storage compared with baseline using creamatocrit as the method 
for fat assessment.30 The aliquots prepared for the various storage conditions were homogenized 
by rocking them in an arc-like fashion 10 times. This might not have been enough to thoroughly 
mix the study samples, which potentially explains why there were differences in the samples at 
30 days, but not at 60 and 90 days compared with baseline. Additionally, while there is a strong 
correlation between the creamatocrit value and the lipid content of HM,42 the authors point out 
the limitations of measuring fat content with this method. There is evidence that the fat globule 
ruptures during frozen storage and subsequent thawing.43 This breakdown, along with the 
continued activity of lipoprotein lipase, causes an increase in free fatty acids. This results in a 
more tightly packed cream layer and, as this is what is measured in a creamatocrit test, can 
produce a false decrease in the creamatocrit reading, which would misrepresent the actual fat 
(and energy) content of the HM.44 
 
Borgo et al., in a 2015 study, assessed the impact of extended freezer storage (−18°C) on the 
concentrations of specific saturated and unsaturated fatty acids in HPDHM over 8 months, with 
measurements taken every 30 days.31 They reported upward, downward, and quadratic trends in 
several saturated and unsaturated fatty acids. However, there were major limitations to this work, 
including the fact that it involved a single sample from one donor, that two time points were 
dropped because of inconsistent findings, and that the study did not describe how the sample was 
mixed during aliquoting, which may impact whether all subsamples had similar fat content. 
 
In 2018, de Waard et al. reported no significant changes in total fat or energy contents, during 8 
months of frozen storage, but a significant increase in protein content (13.4% relative 
increase, p = 0.037).38 This is in contrast to findings by Vieira et al. in 2011, who reported a 
significant decrease in protein concentrations (3.9%, p < 0.001) after 24 hours of frozen 
storage.27 In a 2013 study by García-Lara et al., there was no significant change in total nitrogen, 
which represents protein and nonprotein nitrogen compounds, in HPDHM during 6 months of 
frozen storage.29 
 
The 2011 study by Vieira et al. reported no significant change in lactose concentrations 
(p = 0.427) after 24 hours of frozen storage.27 Similarly, de Waard reported stable carbohydrate 
composition over 8 months of frozen storage.38 In the 2013 study by García-Lara et al., there was 
a small but significant decrease in the carbohydrate content (defined as lactose plus 
oligosaccharides, −0.08 g/dL, 1.7% relative decrease, p = 0.006).29 
 
Overall, these studies suggest that the total fat in HPDHM decreases by 3–8% between 24 hours 
and 180 days of frozen storage, including the nonsignificant reduction reported by de Waard et 
al.38 These decreases correspond to a significant reduction in energy content. Research reflects 
stable carbohydrates during extended frozen storage and inconsistent effects on total protein in 
HPDHM. 
 
Effects on bactericidal capacity and bioactive factors. As part of their 2018 study, Kanaprach 
et al. assessed the effects of extended storage on the growth-promoting activity of fetal intestinal 
cells and the antimicrobial defenses against E. coli in raw and HPDHM.36 The authors reported 
that the antimicrobial activity remained constant in HPDHM for up to 3 months of frozen storage 
(34.0% ± 13.5, compared with 35.9% ± 14.2 at baseline), but exhibited a significant decline at 6 
months (−76.1% ± 23.5, p < 0.005; −323.8% change), indicating an increase in bacterial growth. 
The HPDHM exhibited no significant changes in the growth-promoting activity on fetal 
intestinal cells. 
 
Effects on antioxidative capacity. There is only one published study assessing the antioxidative 
capacity of HPDHM during extended storage under any condition. In 2016, Marinković et 
al.33 found that Holder pasteurization and storage at −20°C for 30 days did not affect static 
oxidation–reduction potential or total nonenzymatic antioxidative capacity. While Holder 
pasteurization caused a significant reduction in ascorbate, superoxide dismutase, and glutathione 
peroxidase activity in HM, frozen storage did not lead to any further changes.33 
 
Effects on pH, acidity, and osmolality. Two studies looked at changes in acidity in HPDHM 
under frozen storage conditions. In 1997, Lepri et al. found that the concentration of l-lactate 
remained constant in HPDHM during the first 35 days of frozen storage; however, after 70 and 
90 days, there was an 18% decrease (significance not assessed).25 Authors speculated that this 
decrease was due to degradation or a change in optical isomeric form. In a 2016 study, Vázquez-
Román et al.34 found that, from baseline to week 1 of storage at −20°C, there was a nonclinically 
significant decrease in the Dornic acidity (3°D to 2°D, p < 0.05) of HPDHM, and this reading 
remained constant over the course of the 3-month study period. Dornic acidity is an alternative 
measure of acidity specific to milk. This method determines the total titratable acidity and results 
are expressed in Dornic degrees, with milk measuring ≥8°D classified as too acidic for 
pasteurization.45 The authors hypothesized that the limited change in Dornic acidity of HPDHM, 
compared with significant changes in raw HM, was due to inactivation of lipase enzymes during 
pasteurization. 
 
Discussion 
 
Summary of findings 
 
It is impossibly difficult to condense data presented in the existing literature into one tidy 
statement. There is very little overlap among these studies with regard to the components 
assessed, analytical methods used, and the length of study period adopted. It would be safe to 
conclude that extended storage affects some aspects of HPDHM more than others. 
 
Under refrigerated storage conditions, the most studied component of unfortified HPDHM was 
bacterial growth. All studies reported no bacterial growth in refrigerated unfortified HPDHM, 
with the longest study duration of 9 days.28,32,35 Importantly, two of these studies were designed 
to reflect feeding room practices, where the refrigerator and the HPDHM bottles were opened 
multiple times a day.28,32 Not all studies reflected these relevant clinical conditions, which may 
have biased their results. There have been only single studies on other components in unfortified 
HPDHM, with no changes reported in total protein, lysozyme activity, sIgA activity, and 
gangliosides for 7 days or more in refrigerated conditions. While the growing body of evidence 
suggests that unfortified HPDHM may be safely stored in the refrigerator for longer than 24 
hours, there is limited information on the refrigerated storage of fortified HPDHM, with one 
small study reporting bacterial growth in one-third of samples mixed with a powder 
fortifier.28 Refrigerated storage of fortified HPDHM is an important area for future research 
given the ubiquitous use of HM fortifiers in the NICU setting.7 Donovan et al. studied fortified 
HM (raw and Holder pasteurized) over 24 hours of refrigerated storage and reported that 
different fortifier types had the potential to change human milk properties, including pH and 
osmolality.23 
 
Under frozen storage conditions, the most studied component of HPDHM was fat, with most 
studies reporting a small but significant decrease over periods of 24 hours to 8 months. The 
mixing and handling procedure for study samples was often not reported in the current body of 
research, which may bias findings about fat, given its propensity to separate from the aqueous 
layer. Additionally, many studies used milliliter volumes of samples, which may bias findings as 
it relates to fat, due to the high ratio of container surface area to sample volume compared with 
what occurs in multiounce bottles of HPDHM. Future studies, especially as they relate to fat, 
should describe mixing and handling protocols for HPDHM and test clinically relevant volumes. 
Carbohydrates appear to be stable during extended freezer storage, whereas findings for protein 
and other components have been inconsistent or only assessed in a single study, suggesting more 
research is needed. 
 
Limitations and future implications 
 
Several limitations were observed throughout the review process. Very few studies have been 
conducted that look exclusively at the effects of long-term storage (refrigerated or frozen) on 
HPDHM. Most address this issue in conjunction with other treatments and outcomes, and 
sometimes results specific to HPDHM were difficult to assess. Small samples size is another 
limitation, along with the use of samples from a single donor rather than samples from pooled 
HPDHM, which would more closely represent HPDHM found in the NICU. Many studies were 
not designed to reflect clinical practices or typical storage volumes, which may bias results. 
 
While Holder pasteurization is employed by the vast majority of milk banks,11–14 future research 
should also focus on the storage of HM processed with techniques other than Holder, given the 
availability of other HM products in the market. Differences in storage duration before 
processing should be accounted for in future studies, as the storage period before processing is 
also likely contributing to changes in milk characteristics. Study periods should extend to 12 
months for frozen storage, and 4–7 days for refrigerated storage given the emerging evidence of 
microbial purity during these time frames. Primary outcomes should include macro- and 
micronutrient retention, and the activity of bioactive proteins. Larger sample sizes and the use of 
pooled donor HM would give more power and relevance to study findings. It would fill a gap if 
future studies were to distinguish between preterm and term HPDHM. With the knowledge that 
the vast majority of NICUs utilize HM fortifiers,7 there is a great need to assess the stability of 
fortified HPDHM beyond 24 hours of refrigerated storage. 
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